PTX 8.00% 4.6¢ prescient therapeutics limited

Ann: PTX-100 progresses to next cohort in basket clinical study, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 113 Posts.
    lightbulb Created with Sketch. 4
    "One patient in 500mg/m2 cohort has multi-chemorefractory PTCL and is stable while and the other patient, who has cutaneous T cell lymphoma (CTCL) and achieved a partial response (PR). Both of these patients have received 9 cycles of PTX-100 treatment."

    great news!
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.